Calvin Stiller

Dr. Stiller is Professor Emeritus, of the University of Western Ontario in the Departments of Medicine and Microbiology and Immunology. Dr. Stiller established the Multi-Organ Transplant Service in London, Ontario, and served as the unit's chief until 1996. During this period, he was principal investigator of the Canadian multi-centre study that established the importance of cyclosporine in transplantation and led to its worldwide use as first-line therapy for transplant rejection. He was the first to demonstrate the efficacy of immunosuppression in newly diagnosed Type 1 Diabetes, establishing the human disease as an immune disorder. He has published over 250 Scientific Papers.

Dr. Stiller is the co-founder of two healthcare funds including the Canadian Medical Discoveries Fund Inc., where he served as Chairman and Chief Executive Officer. He was a Member of the Council and Executive Committee of the Medical Research Council of Canada (1987-1993), was the Founding Chair of the Ontario Research and Development Challenge Fund, is Chair (and co-founder) of the Ontario Institute for Cancer Research and of the Ontario Innovation Trust.

Dr. Stiller serves on the Board of Directors of several Public endeavours and foundations and is Co-founder and Director of MaRS Discovery District. He is also the recipient of numerous awards including the MEDEC Award (1992), the Order of Canada (1995) and the Order of Ontario (2000). He has received three Honorary Doctorates from McMaster University, University of Saskatchewan and University of Western Ontario. He will be inducted into the Canadian Medical Hall of Fame in 2010.